Literature DB >> 9342078

Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience.

F Monpoux, N Sirvent, J Cottalorda, R Mariani, J C Lefbvre.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342078

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

Review 1.  Indinavir: a review of its use in the management of HIV infection.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.

Authors:  A S Bergshoeff; P L A Fraaij; A M C van Rossum; G Verweel; L H Wynne; G A Winchell; R Y Leavitt; B-Y T Nguyen; R de Groot; D M Burger
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 3.  Stavudine: an update of its use in the treatment of HIV infection.

Authors:  M Hurst; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

4.  Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.

Authors:  G Gatti; A Vigano'; N Sala; S Vella; M Bassetti; D Bassetti; N Principi
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

Authors:  D M Burger; A M van Rossum; P W Hugen; M H Suur; N G Hartwig; S P Geelen; H J Scherpbier; R M Hoetelmans; A G Vulto; R de Groot
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients.

Authors:  S C Piscitelli; G Kelly; R E Walker; J Kovacs; J Falloon; R T Davey; S Raje; H Masur; M A Polis
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.